Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CYTK · as of Mar 31, 2025
Ownership Breakdown
390
Institutional Holders
▲ 7 vs Q4
$5.58B
Total Inst. Value
▼ $607.91M vs Q4
124.43M
Shares Outstanding
freeFloat 95.76%
136.63M
13F Shares Held
▲ 4.94M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CYTK largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 15.56M | 13.13% | 13.13% | $625.51B | May 2, 2025 | ▲ 94.4K |
VANGUARD GROUP INC pharmaceutical preparations | 11.85M | 10.00% | 10.00% | $476.23B | May 9, 2025 | ▼ 66.3K |
FMR LLC pharmaceutical preparations | 10.32M | 8.71% | 8.71% | $414.61B | May 12, 2025 | ▼ 478.6K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 9.96M | 8.40% | 8.40% | $400.10B | May 14, 2025 | ▼ 796.9K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 7.99M | 6.74% | 6.74% | $321.07B | May 13, 2025 | ▲ 100.0K |
STATE STREET CORP pharmaceutical preparations | 6.09M | 5.14% | 5.14% | $244.56B | May 15, 2025 | ▼ 82.3K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 3.07M | 2.59% | 2.59% | $123.54B | May 15, 2025 | ▲ 573.9K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.94M | 2.48% | 2.48% | $118.08B | May 13, 2025 | ▲ 96.1K |
RTW INVESTMENTS, LP pharmaceutical preparations | 2.72M | 2.30% | 2.30% | $109.36B | May 15, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 2.70M | 2.28% | 2.28% | $108.63B | May 15, 2025 | ▲ 2.48M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+11.26M shares2
New Positions
first time holders19
Decreased
−3.83M shares0
Sold Out
fully exitedNet shares change (top 50)
+7.42M
+11.26M / −3.83M
Net new holders
+10
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CYTK insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
35
Buy transactions
31
Sell transactions
1.13
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kaye Edward M. MD director | Jun 1, 2026 | Sale | 2,933 | $76.09 | $223.2K | 10.3K | Form 4 ↗ |
Callos Andrew EVP, Chief Commercial Officer | Jun 1, 2026 | Sale | 15,000 | $74.08 | $1.11M | 58.6K | Form 4 ↗ |
PARSHALL B LYNNE director | Jun 1, 2026 | Sale | 5,000 | $74.08 | $370.4K | 15.8K | Form 4 ↗ |
Blum Robert I President & CEO | May 27, 2026 | Sale | 7,500 | $77.21 | $579.1K | 392.8K | Form 4 ↗ |
Bhanji Muna director | May 27, 2026 | Award | 2,851 | — | — | 26.4K | Form 4 ↗ |
Bhanji Muna director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Daly James M director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Daly James M director | May 27, 2026 | Award | 2,851 | — | — | 3.2K | Form 4 ↗ |
Harrington Robert Arthur director | May 27, 2026 | Award | 2,851 | — | — | 21.8K | Form 4 ↗ |
Harrington Robert Arthur director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cytokinetics, Incorporated (CYTK) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.24%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cytokinetics, Incorporated is BLACKROCK, INC., holding approximately 15.56 million shares — equal to 13.13% of outstanding shares — as of March 31, 2025.
A total of 390 institutional investors currently hold CYTK stock, with a combined institutional value of approximately $5.58 billion as of the most recent 13F filing period.
Frequently asked questions
CYTK ownershipCytokinetics, Incorporated (CYTK) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 13.13% stake. Company insiders hold 4.24%. Data sourced from SEC Form 13F as of March 31, 2025.